FORENSIC TOXICOLOGY.NETOkorie Okorocha, J.D., M.S., M.S.Forensic Toxicology Expert Witness

EVIDENCE LIBRARY

On-Site Drug-Testing Device Evidence Matrix

By forensic toxicology working group members

A source-cited matrix comparing on-site drug-testing research by device, specimen, setting, cutoff, confirmation method, and study limitation.

Prepared by THE OKOROCHA FIRM*

Scientific and toxicology content was written by non-toxicologist marketing staff at Connectica, LLC and has not been verified by a trained forensic toxicologist. Read the full Content Disclaimer.

Rapid drug-testing cups, cards, cassettes, and instrument-read panels can provide useful screening information. The studies below do not support one permanent accuracy percentage. They show why performance must be evaluated for the exact device, drug channel, cutoff, specimen matrix, operator, population, and confirmation procedure.

How to read this matrix

  • Screening means an initial class-based or target-based test, commonly an immunoassay.
  • Confirmation means a more chemically specific method, commonly GC-MS or LC-MS/MS.
  • Agreement between two screening methods is not identical to confirmation of every specimen.
  • Historical device results should not be applied automatically to a current product with different antibodies, software, labeling, or cutoffs.
  • A negative screen may mean the target was not detected above that assay’s cutoff. It is not a universal finding that every relevant drug was absent.

Evidence matrix

Year Publication Setting and material What it contributes Important limit
1993 Wu et al., Evaluation of the Triage System for Emergency Drugs-of-Abuse Testing in Urine Emergency urine screening; Triage compared with EMIT; available discordant specimens evaluated by GC/MS Demonstrates drug-channel-specific agreement and the role of cutoff differences Historical product; two immunoassays were the primary comparison and not every discordance was confirmed
1996 de la Torre et al., Clinical Evaluation of the Triage Analytical Device Clinical urine specimens; readers with different laboratory experience; comparison with FPIA and selected chromatography Examines reader skill, prevalence, cutoff proximity, and channel-specific agreement Historical device and comparison method; results do not describe current products
1996 Poklis and O’Neal, Potential for False-Positive Results by the TRIAGE Panel Prepared urine specimens and a historical rapid panel Shows that device handling and specimen conditions can affect a particular assay response Short device-specific letter; not a universal mechanism for all immunoassays
1998 Crouch et al., A Multiple-Site Laboratory Evaluation of Three On-Site Urinalysis Drug-Testing Devices Three laboratories; urine specimens selected by drug class; GC-MS characterization Demonstrates site, analyte, device, cross-reactivity, and near-cutoff considerations Selected specimens and historical workplace-era products and cutoffs
1999 Taylor et al., Accuracy of Five On-Site Immunoassay Drugs-of-Abuse Testing Devices Quality-control and donor urine specimens around SAMHSA cutoffs Identifies discrepancies across products, particularly in amphetamine testing Historical products; challenge design does not equal current routine prevalence
2000 Peace et al., Performance Evaluation of Four On-Site Drug-Testing Devices 222 urine specimens plus prepared concentrations around cutoffs Directly compares four devices and multiple drug channels Findings apply to the tested products, specimens, and decision rules
2001 Gronholm and Lillsunde, A Comparison Between On-Site Immunoassay Drug-Testing Devices and Laboratory Results 800 people; eight urine devices and two oral-fluid devices; laboratory comparison Shows matrix-specific and drug-class-specific performance and user-interpretation differences Historical devices; reported ranges cannot be transferred to a current product
2001 Kadehjian, Performance of Five Non-Instrumented Urine Drug-Testing Devices with Challenging Near-Cutoff Specimens Near-cutoff clinical urine specimens; scientist and non-scientist readers; GC-MS Shows why performance and reader effects must be examined near the cutoff Deliberately difficult specimen set and historical products; not a universal accuracy percentage
2002 George and Braithwaite, Use of On-Site Testing for Drugs of Abuse Review of near-patient testing devices Summarizes labeling, subjective endpoint, false-result, and confirmation concerns Review article; current product instructions and validation control present use
2002 Crouch et al., A Field Evaluation of Five On-Site Drug-Testing Devices Two police agencies; 800 DUI arrestees; urine devices and mass-spectrometric follow-up Adds real-world field use and shows how confirmation scope changes apparent discrepancies Only a sample of screen-negative specimens was confirmed; historical products and cutoffs
2005 Melanson, Implementing Drug-of-Abuse Testing at the Point of Care Implementation review Provides a framework for menu, cross-reactivity, quality control, operator competency, reporting, and cost Historical review with emphasis on one product family
2008 Lewandrowski et al., Implementation of Point-of-Care Rapid Urine Testing in an Emergency Department Academic emergency department Shows faster turnaround and shorter reported length of stay while documenting method-dependent performance differences Operational study at one center; speed does not create chemical specificity
2009 Hikiji et al., False Negative Result for Amphetamines on the Triage Drug of Abuse Panel? Postmortem case and experimental follow-up Demonstrates a device-specific false-negative mechanism involving methamphetamine and chlorpromazine metabolites One case and one device family; cannot be generalized to other assays or mixtures
2012 Attema-de Jonge et al., Performance of Three Point-of-Care Urinalysis Test Devices in the Emergency Department 80 emergency-department urine specimens; three devices; laboratory comparison and confirmation Shows analyte-specific sensitivity, objective reading, and quality-control advantages Small single-center study; product rankings are not permanent
2014 Saitman et al., False-Positive Interferences of Common Urine Drug Screen Immunoassays Review of published interferences Supports treating immunoassay positives as presumptive until confirmed independently Many interferents are assay-specific and some evidence is case-report level
2014 Toubou et al., Detection of Abused Drugs in Human Blood Using Oratect III Specially acidified, filtered whole-blood preparation tested with an oral-fluid device Demonstrates an optimized laboratory adaptation to an alternative matrix Not direct routine use on untreated blood; still a screening approach
2015 Tominaga et al., Efficacy of Drug Screening in Forensic Autopsy Review of 2,996 autopsies over 18.5 years Shows additional findings from systematic GC/MS and selected LC-MS/MS beyond on-site screening Retrospective single-institute workflow spanning major technology changes
2015 Tominaga, Michiue, and Maeda, Evaluation of Triage-TOX in Routine Forensic Autopsy Urine and pericardial-fluid specimens from 66 autopsy cases; three devices Demonstrates matrix-specific and drug-channel-specific false-positive and false-negative findings Small selected postmortem series; results should not be generalized beyond tested conditions
2016 Johnson-Davis et al., A Retrospective Analysis of Urine Immunoassay True Positive Rates National reference laboratory; thousands of screens followed by mass-spectrometric confirmation Shows that the proportion confirmed varies substantially by assay and drug class Laboratory, reagent, population, cutoff, and confirmation rules are specific to the dataset

What the studies establish together

1. The product name matters

An immunoassay is not a generic reagent. Antibody design, calibrator selection, target compound, metabolite response, and cross-reactivity differ across manufacturers and generations.

2. Each drug channel must be evaluated separately

A multi-panel device can perform differently for amphetamines, cannabinoids, opiates, benzodiazepines, cocaine metabolite, and other channels. One overall percentage can conceal a weak or poorly characterized channel.

3. Near-cutoff specimens deserve special attention

A small analytical or procedural difference can change the qualitative classification when a specimen response is near the decision cutoff. The cutoff does not prove absence below it or certainty above it.

4. Specimen matrix is part of the method

Urine, oral fluid, blood, and postmortem fluids have different collection, analyte, concentration, and interference profiles. A device validated for one matrix should not be assumed valid for another.

5. Operators and controls are evidence

Visual interpretation, reading time, storage, lot condition, calibration, controls, competency, and documentation are not merely administrative details. They determine whether the reported classification can be reproduced and defended.

6. Confirmation must match the question

A confirmation method detects only the analytes it includes. The review should identify its analyte menu, cutoffs, separation, identification criteria, raw data, controls, and ability to resolve relevant metabolites or isomers.

Records for a device-specific review

  1. manufacturer, device, model, lot, expiration date, and photograph;
  2. package insert and drug-channel cutoffs in effect on the test date;
  3. specimen type, collection time, storage, validity, and chain of custody;
  4. operator training, competency, reading time, and result documentation;
  5. calibration, positive and negative controls, errors, and corrective actions;
  6. complete medication, nonprescription product, and supplement history;
  7. screening and confirmation reports, including amended versions;
  8. confirmation analyte menu, cutoffs, chromatograms, spectra or transitions, calculations, and batch controls; and
  9. laboratory procedures, validation or verification, and reporting rules.

Frequently asked questions

Is a positive on-site drug test a confirmed identification?

No. An on-site immunoassay result is generally a presumptive screening result. A chemically specific confirmation method, with an analyte menu and decision criteria suited to the question, is needed before treating the result as a confirmed identification.

Can a negative on-site test prove that no drug was present?

No. A negative result means the device did not produce a positive response for its tested channel under its cutoff and operating conditions. It does not establish that every relevant drug or metabolite was absent.

Does one published accuracy percentage apply to every rapid drug-testing device?

No. Performance depends on the exact device, drug channel, antibodies, cutoff, specimen matrix, operator, study population, comparator, and confirmation procedure. Results from a historical product should not be transferred automatically to a current device.

What records are most important when reviewing a disputed result?

Start with the device and lot, package insert, cutoff, specimen and collection records, timing, operator training, photographs or instrument output, quality-control records, medication history, and the complete screening and confirmation reports. The confirmation analyte list and raw analytical data may be essential.

Sources

Related scientific guide: Immunoassay Drug Screen Scientific Guide

Related litigation checklist: Rapid Urine Drug Test Litigation Records

General educational and marketing material only. It is not legal advice, expert opinion, or a statement of scientific fact. Read the full Content Disclaimer.